KR20230079054A - 폐섬유증을 치료하기 위한 펜레티나이드 또는 이의 유사체의 용도 - Google Patents

폐섬유증을 치료하기 위한 펜레티나이드 또는 이의 유사체의 용도 Download PDF

Info

Publication number
KR20230079054A
KR20230079054A KR1020237010037A KR20237010037A KR20230079054A KR 20230079054 A KR20230079054 A KR 20230079054A KR 1020237010037 A KR1020237010037 A KR 1020237010037A KR 20237010037 A KR20237010037 A KR 20237010037A KR 20230079054 A KR20230079054 A KR 20230079054A
Authority
KR
South Korea
Prior art keywords
fenretinide
analog
pharmaceutically acceptable
acceptable salt
administered
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020237010037A
Other languages
English (en)
Korean (ko)
Inventor
라두 피슬라리우
이레네이 키아닉카
Original Assignee
로랑 파마슈티컬스 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 로랑 파마슈티컬스 인코포레이티드 filed Critical 로랑 파마슈티컬스 인코포레이티드
Publication of KR20230079054A publication Critical patent/KR20230079054A/ko
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Pulmonology (AREA)
  • Dispersion Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
KR1020237010037A 2020-08-25 2021-08-19 폐섬유증을 치료하기 위한 펜레티나이드 또는 이의 유사체의 용도 Pending KR20230079054A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063069881P 2020-08-25 2020-08-25
US63/069,881 2020-08-25
PCT/CA2021/051148 WO2022040782A1 (en) 2020-08-25 2021-08-19 Use of fenretinide or an analogue thereof to treat pulmonary fibrosis

Publications (1)

Publication Number Publication Date
KR20230079054A true KR20230079054A (ko) 2023-06-05

Family

ID=80352354

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020237010037A Pending KR20230079054A (ko) 2020-08-25 2021-08-19 폐섬유증을 치료하기 위한 펜레티나이드 또는 이의 유사체의 용도

Country Status (10)

Country Link
US (1) US20230310352A1 (https=)
EP (1) EP4203931A4 (https=)
JP (1) JP2023539847A (https=)
KR (1) KR20230079054A (https=)
CN (1) CN116437904A (https=)
AU (1) AU2021329999A1 (https=)
BR (1) BR112023003481A2 (https=)
CA (1) CA3128648A1 (https=)
MX (1) MX2023002347A (https=)
WO (1) WO2022040782A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20250142485A (ko) 2024-03-22 2025-09-30 경희대학교 산학협력단 폐섬유증 예방 또는 치료용 조성물

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011127164A2 (en) * 2010-04-08 2011-10-13 Fate Therapeutics, Inc. Pharmaceutical compositions to treat fibrosis
TWI658830B (zh) * 2011-06-08 2019-05-11 日東電工股份有限公司 Ｈｓｐ47表現調控強化用類視色素脂質體
US10406127B2 (en) * 2014-07-25 2019-09-10 Laurent Pharmaceuticals Solid oral formulation of fenretinide

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20250142485A (ko) 2024-03-22 2025-09-30 경희대학교 산학협력단 폐섬유증 예방 또는 치료용 조성물

Also Published As

Publication number Publication date
BR112023003481A2 (pt) 2023-05-09
WO2022040782A1 (en) 2022-03-03
EP4203931A4 (en) 2024-11-13
JP2023539847A (ja) 2023-09-20
EP4203931A1 (en) 2023-07-05
MX2023002347A (es) 2023-04-20
CN116437904A (zh) 2023-07-14
US20230310352A1 (en) 2023-10-05
AU2021329999A1 (en) 2023-03-23
CA3128648A1 (en) 2022-02-25

Similar Documents

Publication Publication Date Title
KR20200014736A (ko) 니라파립 조성물
JP2014520842A (ja) モンテルカストおよびリボセチリジン配合のカプセル製剤
US20230190754A1 (en) Therapeutic combinations for the treatment of Progressive Fibrosing interstitial lung diseases
US20230248716A1 (en) Pharmaceutical compositions comprising nitroxoline lysinate, preparation method therefor and use thereof
JP2015503579A (ja) レボセチリジンまたはその医薬的に許容される塩およびモンテルカストまたはその医薬的に許容される塩を含む経口投与用安定医薬製剤
KR20150139830A (ko) 신경변성 및 기타 질환의 치료를 위한 조성물 및 방법
AU2025205402A1 (en) New oral pharmaceutical composition and dose regimen for the therapy of progressive fibrosing interstitial lung diseases
KR20230079054A (ko) 폐섬유증을 치료하기 위한 펜레티나이드 또는 이의 유사체의 용도
JP6088429B2 (ja) 関節リウマチなどの自己免疫疾患の治療の改善方法
US20250360181A1 (en) Use of cyclosporine analogues for treating fibrosis
JP4045301B2 (ja) 肺胞破壊によって生じる肺疾患の治療または予防のためのクラリスロマイシンまたはその塩
WO2019009359A1 (ja) 経鼻投与用医薬組成物
JP2024516852A (ja) 甲状腺ホルモン模倣薬の、脂肪酸アミド加水分解酵素（ｆａａｈ）により切断可能なプロドラッグ、および末梢制限ｆａａｈ阻害剤との組合せ
JP2021522177A (ja) イオン輸送体の活性を増強するための組成物および方法ならびにその使用
US20250134908A1 (en) Therapeutics and method for treating osteoarthritis
HK40115216A (en) New oral pharmaceutical composition and dose regimen for the therapy of progressive fibrosing interstitial lung diseases
HK40118402A (en) New therapeutic combinations for the treatment of progressive fibrosing interstitial lung diseases
HK40113149A (en) New oral pharmaceutical composition and dose regimen for the therapy of progressive fibrosing interstitial lung diseases
HK40113149B (en) New oral pharmaceutical composition and dose regimen for the therapy of progressive fibrosing interstitial lung diseases
AU2021242812A1 (en) Use of fenretinide for the treatment of SARS-corona virus infection
TW202410903A (zh) 治療肌肉萎縮性脊髓側索硬化症之方法及組成物
CN111481544A (zh) 药物制剂
WO2018160637A1 (en) Drug combinations for cerebrovascular disease
BR112018070626B1 (pt) Formulação farmacêutica e uso da mesma
HK1200337B (en) Stable pharmaceutical formulation for oral administration comprising levocetirizine or a pharmaceutically acceptable salt thereof, and montelukast or a pharmaceutically acceptable salt thereof

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

A201 Request for examination
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

D21 Rejection of application intended

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D21-EXM-PE0902 (AS PROVIDED BY THE NATIONAL OFFICE)

PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902